Stock ALTIMMUNE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Altimmune Inc Nyse

Equities

US71714G1022

Biotechnology & Medical Research

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Altimmune Inc
Apr. 02 Transcript : Altimmune, Inc. - Special Call
Mar. 27 Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B MT

Business Summary

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Sales per Business

USD in Million2022Weight2023Weight Delta
Treatments for Various Diseases and Disorders, and Vaccines
100.0 %
0 100.0 % 0 100.0 % -726.47%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -726.47%

Managers

Managers TitleAgeSince
Vipin K. Garg CEO
 Chief Executive Officer 67 18-11-29
Richard Eisenstadt DFI
 Director of Finance/CFO 66 21-12-30
Anthony Blandin CMP
 Compliance Officer - 22-01-31
M. Roberts CTO
 Chief Tech/Sci/R&D Officer 65 12-11-30
Bertrand Georges CTO
 Chief Tech/Sci/R&D Officer - 15-02-28
M. Harris CTO
 Chief Tech/Sci/R&D Officer 71 19-09-08
Karen Smith PRN
 Corporate Officer/Principal - 20-08-31
Andrew Shutterly AUD
 Comptroller/Controller/Auditor - 20-09-30
Karen Smith
56 -
Raymond Jordt PRN
 Corporate Officer/Principal 52 22-12-31

Members of the board

Members of the board TitleAgeSince
Mitchel Sayare CHM
 Chairman 76 10-03-31
Mack Gill BRD
 Director/Board Member 72 04-07-31
Philip Hodges BRD
 Director/Board Member 56 03-08-31
Vipin K. Garg CEO
 Chief Executive Officer 67 18-11-29
David Drutz BRD
 Director/Board Member 86 09-12-31
Wayne Pisano BRD
 Director/Board Member 69 18-08-29
Diane Jorkasky BRD
 Director/Board Member 72 20-05-10
Catherine Sohn BRD
 Director/Board Member 71 23-03-22
Klaus Schafer BRD
 Director/Board Member 74 12-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,895,286 70,345,020 ( 99.22 %) 0 99.22 %

Shareholders

NameEquities%Valuation
SSgA Funds Management, Inc.
16.10 %
8,649,270 16.10 % 88 M $
Ameriprise Trust Co.
7.787 %
4,183,682 7.787 % 43 M $
BlackRock Advisors LLC
7.249 %
3,894,837 7.249 % 40 M $
Vanguard Fiduciary Trust Co.
6.648 %
3,571,972 6.648 % 36 M $
Millennium Management LLC
5.420 %
2,911,937 5.420 % 30 M $
Tang Capital Management LLC
5.118 %
2,750,000 5.118 % 28 M $
Teachers Advisors LLC
3.215 %
1,727,316 3.215 % 18 M $
Point72 Asset Management LP
2.320 %
1,246,500 2.320 % 13 M $
Geode Capital Management LLC
2.221 %
1,193,528 2.221 % 12 M $
Morgan Stanley Investment Management, Inc.
1.937 %
1,040,901 1.937 % 11 M $

Company contact information

Altimmune, Inc.

910 Clopper Road Suite 201S

20878, Gaithersburg

+240 654 1450

http://www.altimmune.com
address Altimmune Inc

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALT Stock
  4. Stock
  5. Company Altimmune Inc